ELVN Enliven Therapeutics
- 27.650
- +0.020+0.07%
Enliven Therapeutics News
Enliven Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Hohl Benjamin
Enliven Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-BlackRock, Inc.(6.2%)
Enliven Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Patel Anish
Enliven Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Hohl Benjamin
Enliven Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Kintz Samuel
Enliven Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Lyssikatos Joseph P
Enliven Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Heyman Richard A.
Enliven Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Collins Helen Louise
Enliven Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Heyman Richard A.
Enliven Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Lyssikatos Joseph P
Enliven Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Kintz Samuel
Enliven Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Ballal Rahul D.
Enliven Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Lyssikatos Joseph P
Enliven Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Kintz Samuel
Enliven Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Hohl Benjamin
Enliven Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Heyman Richard A.
Enliven Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Lyssikatos Joseph P
Enliven Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Kintz Samuel
Enliven Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Hohl Benjamin
Enliven Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Heyman Richard A.
Analysis
Price Target
No Data
No Data